Hye-Ok Kubo; Douglas A. Canders; Malcolm Scammells; Philip Frugier
Abstract
In this essay, we declare a comprehensive discussion on the responses of multiple sclerosis (MS) and the corresponding efficacy of the action associated via IL-6 (Interleukin-6), including: the significance on the topic; the mechanisms or relevant factors that are representative in previous studies; and whether drugs targeting IL-6 show efficacy from an impact point of view. Multiple sclerosis (MS) is a chronic neuroinflammatory disease, and more than 3 million individuals are affected. Its highest incidence is observed in Western Europe, the United States, and some peripheral countries, where it has been increasing at a rate of 3.5% annually, and the increase rate is expected to remain high in the subsequent few years. IL-6, as an important pro-inflammatory factor that can initiate a pivotal effect, mediates Th1 or Th17 change over, and in the disease process, promotes aggravation or deterioration of autoreactive lymphocyte responses, enhances the development of harmful cytokines, and reduces the settlement of T or B lymphocytes. Thus, we tend to orient the latest views on finding multiple sclerosis’ efficacy results by IL-6 action. The original research study included 49 articles. A general amount of 133 different related pathways were obtained. Research of the initial 20 articles was reported as an outcome summary of MS via the acquisition of the number of unique pathways dependence on IL-6 levels and related P values.
Keywords: Multiple sclerosis; IL-6; Proinflammatory cytokine; Myelin
References
1. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8:647–56. [PubMed]
2. Rangachari M, Kuchroo VK. Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun 2013;45:31–9. [PubMed]
3. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 2007;178:39–48. [PubMed]
4. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6(3): 315–325. [PubMed]
5. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis.Brain Pathol 1996; 6:243–57. [PubMed]
6. Racke MK, Bonomo A, Scott DE et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med 1994; 180:1961–6. [PubMed]
7. Ohtsuka T. Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801–806. [PubMed]
8. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13:357–368. [PubMed]
9. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121:3375–3383. [PubMed]
10. Althoff K, Reddy P, Voltz N, Rose-John S, Müllberg J. Shedding of interleukin-6 receptor and tumor necrosis factor α. Eur J Biochem 2000; 267: 2624–2631. [PubMed]
11. Terao M, Murota H, Kitaba S, Katayama I. Tumor necrosis factor-α processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp Dermatol 2010; 19:38–43. [PubMed]
12. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007; 110:1748–1755. [PubMed]
13. Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012; 39:1120–1124. [PubMed]
14. Hügle T, O’Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M et al. Tumor necrosis factor co-stimulated T-lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthr Rheumat 2012; 65:481–491.
15. Saito F, Tasaka S, Inoue K-i, Miyamoto K, Nakano Y, Ogawa Y et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008; 38:566–571. [PubMed]
16. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82:1120–1126.
17. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103:1253–1260. [PubMed]
18. Radstake TRDJ, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS ONE 2009; 4:e5981. [PubMed]
19. Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010; 49:2408–2412. [PubMed]
20. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2008; 68:620–8. [PubMed]
